Current and emerging approaches to managing peripheral artery disease: a specialist review

Peripheral artery disease (PAD) affects over 113 million people worldwide and is a marker of systemic atherosclerosis associated with significant cardiovascular and limb morbidity. While classic claudication is the most recognised presentation, PAD often manifests asymptomatically or with atypical symptoms, particularly in high-risk populations such as those with diabetes mellitus and chronic kidney disease. In advanced stages, chronic limb-threatening ischaemia (CLTI) confers high risks of amputation and mortality, underscoring the need for early diagnosis and aggressive management. Atherosclerosis accounts for >90% of PAD cases, while non-atherosclerotic causes are rare but critical to recognise, particularly in younger patients. History and physical exam remain the cornerstone of PAD diagnosis; however, non-invasive haemodynamic assessments remain necessary diagnostic adjuncts. In symptomatic patients, duplex arterial ultrasound, CT or magnetic resonance angiography imaging can also be useful. Optimal management hinges on risk factor modification, including smoking cessation, blood pressure control, lipid-lowering therapy, diet, supervised exercise therapy and glycaemic control. Antiplatelet therapy remains first-line, while dual pathway inhibition reduces cardiovascular and limb events in high-risk patients. Supervised exercise therapy is a cornerstone of claudication management, often delaying or avoiding revascularisation. Revascularisation should be reserved for lifestyle-limiting claudication refractory to medical therapy or for CLTI, with an appropriate approach (surgical, endovascular or hybrid) guided by anatomy, comorbidities and shared decision making. The 2024 American Heart Association/American College of Cardiology guidelines reinforce a patient-centred, evidence-based approach integrating medical therapy, functional assessment and timely intervention. Accordingly, this review provides a practical, contemporary framework for the diagnosis and management of atherosclerotic PAD, with consideration of future directions in PAD care.

Authors

Institutions

Publication Details

Journal
Heart
Published
2026-04-11
DOI
https://doi.org/10.1136/heartjnl-2025-326532
Primary Topic
Peripheral Artery Disease Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Current and emerging approaches to managing peripheral artery disease: a specialist review

Mehdi H. Shishehbor, Leen Hussein, Ashkan Yahyavi, Abbas Mohammadi
Heart
Peripheral Artery Disease Management
article

Current and emerging approaches to managing peripheral artery disease: a specialist review

Mehdi H. Shishehbor, Leen Hussein, Ashkan Yahyavi, Abbas Mohammadi
article en

Abstract

Peripheral artery disease (PAD) affects over 113 million people worldwide and is a marker of systemic atherosclerosis associated with significant cardiovascular and limb morbidity. While classic claudication is the most recognised presentation, PAD often manifests asymptomatically or with atypical symptoms, particularly in high-risk populations such as those with diabetes mellitus and chronic kidney disease. In advanced stages, chronic limb-threatening ischaemia (CLTI) confers high risks of amputation and mortality, underscoring the need for early diagnosis and aggressive management. Atherosclerosis accounts for >90% of PAD cases, while non-atherosclerotic causes are rare but critical to recognise, particularly in younger patients. History and physical exam remain the cornerstone of PAD diagnosis; however, non-invasive haemodynamic assessments remain necessary diagnostic adjuncts. In symptomatic patients, duplex arterial ultrasound, CT or magnetic resonance angiography imaging can also be useful. Optimal management hinges on risk factor modification, including smoking cessation, blood pressure control, lipid-lowering therapy, diet, supervised exercise therapy and glycaemic control. Antiplatelet therapy remains first-line, while dual pathway inhibition reduces cardiovascular and limb events in high-risk patients. Supervised exercise therapy is a cornerstone of claudication management, often delaying or avoiding revascularisation. Revascularisation should be reserved for lifestyle-limiting claudication refractory to medical therapy or for CLTI, with an appropriate approach (surgical, endovascular or hybrid) guided by anatomy, comorbidities and shared decision making. The 2024 American Heart Association/American College of Cardiology guidelines reinforce a patient-centred, evidence-based approach integrating medical therapy, functional assessment and timely intervention. Accordingly, this review provides a practical, contemporary framework for the diagnosis and management of atherosclerotic PAD, with consideration of future directions in PAD care.

Heart
University Hospitals of Cleveland (US), Valley Health System (US)
Good health and well-being
Openalex Percentile: Top 20%
Peripheral Artery Disease Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.